Literature DB >> 15364114

Characterization of the human immune response to the UK anthrax vaccine.

Les Baillie1, Tim Townend, Nicki Walker, Ulla Eriksson, Diane Williamson.   

Abstract

The anthrax bipartite lethal toxin (protective antigen (PA) and lethal factor (LF))-specific antibody responses of humans receiving the UK licensed anthrax vaccine were determined. The PA-specific IgG response peaked two weeks post immunization and fell back to pre-boost levels by week 12. The heterogeneity of the host population modulated the extent of the PA-specific antibody response. Significantly lower levels of LF-specific antibodies were also detected. Vaccinated individuals recognized the same PA epitope as the protective mouse lethal toxin neutralizing monoclonal 2D3 suggesting that this may also be a target for human protection.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15364114     DOI： 10.1016/j.femsim.2004.05.011

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN： 0928-8244


  21 in total

1.  Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

Authors:  Sherry R Crowe; Linda L Ash; Renata J M Engler; Jimmy D Ballard; John B Harley; A Darise Farris; Judith A James
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

3.  Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.

Authors:  Eric K Dumas; Lori Garman; Hannah Cuthbertson; Sue Charlton; Bassam Hallis; Renata J M Engler; Shyamal Choudhari; William D Picking; Judith A James; A Darise Farris
Journal:  Vaccine       Date:  2017-05-11       Impact factor: 3.641

4.  Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.

Authors:  C K Cote; L Kaatz; J Reinhardt; J Bozue; S A Tobery; A D Bassett; P Sanz; S C Darnell; F Alem; A D O'Brien; S L Welkos
Journal:  J Med Microbiol       Date:  2012-07-05       Impact factor: 2.472

5.  The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.

Authors:  Karen E Brenneman; Mehmet Doganay; Arya Akmal; Stanley Goldman; Darrell R Galloway; Alfred J Mateczun; Alan S Cross; Leslie W Baillie
Journal:  FEMS Immunol Med Microbiol       Date:  2011-04-15

Review 6.  An overview of anthrax infection including the recently identified form of disease in injection drug users.

Authors:  Caitlin W Hicks; Daniel A Sweeney; Xizhong Cui; Yan Li; Peter Q Eichacker
Journal:  Intensive Care Med       Date:  2012-04-24       Impact factor: 17.440

7.  Polymeric glycoconjugates protect and activate macrophages to promote killing of Bacillus cereus spores during phagocytosis.

Authors:  Olga Tarasenko; Elizabeth Burton; Lee Soderberg; Pierre Alusta
Journal:  Glycoconj J       Date:  2008-01-17       Impact factor: 2.916

8.  The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-Specific CD4+ T cells with a phenotype distinct from that of naive PA T cells.

Authors:  William W Kwok; Junbao Yang; Eddie James; John Bui; Laurie Huston; Andrew R Wiesen; Michelle Roti
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

9.  Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies.

Authors:  Nareen Abboud; Magdia De Jesus; Antonio Nakouzi; Radames J B Cordero; Mario Pujato; András Fiser; Johanna Rivera; Arturo Casadevall
Journal:  J Biol Chem       Date:  2009-07-18       Impact factor: 5.157

10.  Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.

Authors:  Mary Ann Pohl; Johanna Rivera; Antonio Nakouzi; Siu-Kei Chow; Arturo Casadevall
Journal:  Infect Immun       Date:  2013-03-18       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.